Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and N-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide

A method of treating an immunological disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising

• a first component comprising 5-methyl-4′-trifluoromethyl-4-isoxazolecarboxanilide;
• a second component comprising a compound of formula I
• or a sterioisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I;
• and
• a third component comprising a pharmaceutically tolerated excipient;
• wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 15% of the first component.

A method of treating a disease comprising administering to a patient in need of such treatment, a therapeutically effective amount of a solid composition comprising a first component comprising 5-methyl-4′-trifluoromethyl-4-isoxazolecarboxanilide;

• a second component comprising a compound of formula I
• or a stereoisomeric form of the compound of formula I, or a physiologically tolerated salt of the compound of formula I;
• and
• a third component comprising a pharmaceutically tolerated excipient;
• wherein the first component has a concentration from about 2 to about 20 mg and the second component has a concentration from about 0.3% to about 15% of the first component, and wherein the disease is atopic dermatitis, asthma, urticaria, rhinitis, uveitis, type II diabetes, cystic fibrosis, colitis, or hepatic fibrosis.